Free Allergy and Immunology CME

Physicians specializing in Allergy or Dermatology.

Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy emphasizes the use of IVIg in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy.

The presentation consists of a single lecture, Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy, with discussion by Roy L. Freeman, MD, Richard J. Barohn, MD and Kenneth C. Gorson, MD.

After viewing Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy, you will be better able to :
• Conduct a thorough and timely evaluation and differential diagnosis of patients with chronic inflammatory demyelinating polyneuropathy.
• Devise appropriate treatment regimen for the effective management of chronic inflammatory polyneuropathy based on guidelines and clinical evidence.

Target Audiences:
This program is intended for US-based neurologists, immunologists, physician assistants, nurse practitioners, and nurses who manage, or have an interest in managing patients with immune-mediated neuropathies.

Activity Description / Statement of Need:

Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may be associated with permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Globally, it affects 0.1-1% of people, it is a common comorbidity of patients with psoriasis, affecting up to a quarter of those with moderate-to-severe disease. affecting them in a quarter percent of the U.S. population. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible. In all, patients with PsA incur about four times the direct medical costs as compared to the average medical patient.

This accredited educational activity identifies the critical components of the management process and offer solutions to close gaps in diagnosis and care, with the ultimate goals being the improvement of psoriatic arthritis management, treatment adherence, and health and cost outcomes. 

Target Audience:

The following HCPs: rheumatologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in rheumatology and immunology; and any other HCPs with an interest in or who clinically encounter patients with PsA.

Activity Description / Statement of Need:

In this online, self-learning activity:

Atopic dermatitis (AD) is a chronic, highly pruritic inflammatory skin disease that is one of the most common skin disorders in children but may develop at any age. It affects 15-30% of children and two to ten percent of adults in developed countries, and between 10-30% of children who have the condition continue to experience it in adulthood. AD is thought to arise from a complicated interplay between multiple genes and environmental triggers, with known risk factors including family history and loss of function mutations in filaggrin. Complications include food allergy, asthma, and allergic rhinitis, and aside from genetics, its pathophysiology involves T-cell mediated inflammation and epidermal dysfunction. The disease is associated with a considerable healthcare burden placed on patients and their families; pruritis aside, patients not uncommonly suffer a loss of sleep and experience secondary infections, anxiety, and depression.

Target Audience:

The following HCPs: Pediatric and adult dermatologists, allergists, and internists; physician assistants, nurse practitioners, and pharmacists who treat patients with dermatologic conditions; and any other HCPs with an interest in or who diagnose, treat, or manage patients with AD.